Cencora, Inc. $COR Shares Purchased by Police & Firemen s Retirement System of New Jersey

Police & Firemen s Retirement System of New Jersey raised its holdings in Cencora, Inc. (NYSE:COR) by 10.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 27,773 shares of the company’s stock after acquiring an additional 2,613 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Cencora were worth $8,328,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in COR. Invesco Ltd. increased its stake in Cencora by 42.1% in the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after purchasing an additional 1,364,433 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Cencora by 4,459.6% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after acquiring an additional 975,362 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after acquiring an additional 787,858 shares during the period. Nuveen LLC acquired a new stake in shares of Cencora in the first quarter worth approximately $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in Cencora by 144.4% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock valued at $206,641,000 after purchasing an additional 439,008 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Up 0.5%

Shares of COR opened at $365.06 on Friday. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $366.17. The stock’s 50-day moving average is $319.97 and its two-hundred day moving average is $301.57. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The stock has a market cap of $70.78 billion, a PE ratio of 37.56, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue was up 5.9% on a year-over-year basis. During the same period last year, the business posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Analysts Set New Price Targets

A number of brokerages have weighed in on COR. Wells Fargo & Company lifted their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday. Mizuho increased their target price on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group lifted their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. TD Cowen upped their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $371.09.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.